Jagsonpal Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is primarily engaged in the manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients (APIs). Its Gynaecology products include Divatrone, Endoreg, Cystelia-M, Fibristone, Yuliprist, Deereg, and Lycored Softgel. Its Orthopaedics products include JP Tone Up, Metadec 50 Injection, Metadec 25 Injection, Indocap SR, and Indocap, Colla-2. Its other products include Equirex, Doxypal DR-L, JP Tone Syrup, and Lycored Syrup.

Employees

1,399

Sector

Pharmaceuticals

Calendar

09-04 Ex-dividend date - 4 INR

More about the company

Quotes

Date	Price	Change	Volume
26-08-05	₹239.62	+1.32%	128,750
26-08-04	₹236.50	+0.48%	111,099
26-08-03	₹235.37	+1.98%	182,821
26-07-31	₹230.80	-2.22%	451,990
26-07-30	₹236.04	+2.40%	14,104,509

Delayed Quote NSE India S.E.

More quotes

Income Statement and Estimates

More financial data

Delayed NSE India S.E. Other stock markets 07:05:08 2026-08-05 EDT			5-day change	1st Jan Change
239.62 ^INR	+1.32%		+4.14%	+24.62%

07-30	Jagsonpal Pharmaceuticals Limited announces Annual dividend, payable on October 18, 2026	CI
07-29	Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI

Market Cap	12.32B 130M 112M 105M 96.35M 182M 184M 1.24B 483M 6.16B 486M 476M 20.41B	P/E 2024	32.7x	P/E 2025	26.4x
Enterprise Value	11.13B 117M 102M 94.71M 87.01M 165M 166M 1.12B 437M 5.56B 439M 430M 18.43B	EV / Sales 2024	2.84x	EV / Sales 2025	4.92x
Free-Float	23.91%	Yield 2024	1.81%	Yield 2025	1.15%

07-30	Jagsonpal Pharmaceuticals Limited announces Annual dividend, payable on October 18, 2026	CI
07-29	Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2026	CI
07-16	Jagsonpal Pharmaceuticals Limited completed the acquisition of 85% stake in Aequitas Healthcare Private Limited.	CI
06-28	Jagsonpal Pharmaceuticals Limited entered into a definitive agreement to acquire 85% stake in Aequitas Healthcare Private Limited for approximately INR 210 million.	CI
05-25	Tranche Update on Jagsonpal Pharmaceuticals Limited's Equity Buyback Plan announced on March 12, 2026.	CI
05-18	Jagsonpal Pharmaceuticals Limited Announces Resignation of Pallavi Dinodia Gupta as the Independent Director, Effective May 18, 2026	CI
05-13	Jagsonpal Pharmaceuticals Limited's Equity Buyback announced on March 12, 2026, has closed with 1,600,000 shares, representing 2.44% for INR 400 million.	CI
05-07	Jagsonpal Pharmaceuticals Sets Dates for INR400 Million Buyback	MT
04-28	Jagsonpal Pharmaceuticals Net Profit Jumps in Fiscal Q4	MT
04-27	Jagsonpal Pharmaceuticals Limited Recommends Dividend for the Financial Year Ended March 31, 2026	CI
04-27	Jagsonpal Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026	CI
04-27	Jagsonpal Pharmaceuticals passes buy-back resolution	RE
03-13	Jagsonpal Pharmaceuticals gets order for tax demand of 48.2 million rupees	RE

22-08-29	Jagsonpal Pharmaceuticals : ESOP/ESPS/SBEB Scheme	PU
22-08-16	Jagsonpal Pharmaceuticals : Reply to Clarification Sought	PU
22-07-16	Jagsonpal Pharmaceuticals : Appointment	PU

Jagsonpal Pharmaceuticals Limited Stock

Stocks

JAGSNPHARM

INE048B01035

Pharmaceuticals

Valuation: Jagsonpal Pharmaceuticals Limited

Chart: Jagsonpal Pharmaceuticals Limited

Latest news : Jagsonpal Pharmaceuticals Limited

Press Releases: Jagsonpal Pharmaceuticals Limited

Quotes and Performance

Course Extremes

Managers and Directors: Jagsonpal Pharmaceuticals Limited

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+1.50%
1 week	+4.14%
Current month	+4.00%
1 month	+1.31%
3 months	+15.93%
6 months	+41.14%
Current year	+24.62%

1 week	226.79	263.7
1 month	214.24	263.7
Current year	155	264.5
1 year	155	281.7
3 years	109.44	328.04
5 years	49.2	328.04
10 years	6.5	328.04

Manager	Title	Age	Since
Manish Gupta CEO	Chief Executive Officer	59	2022-07-15
Nirav Niranjankumar Vora DFI	Director of Finance/CFO	-	2025-10-06
Amrut Medhekar COO	Chief Operating Officer	-	2025-09-03

Director	Title	Age	Since
Rajpal Singh Kochhar CHM	Chairman	69	2013-12-03
Harsha Raghavan CHM	Chairman	54	2022-07-15
Manish Gupta BRD	Director/Board Member	59	2022-07-15

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
JAGSONPAL PHARMACEUTICALS LIMITED	+1.32%	+4.14%	-13.76%	+36.63%	164M
ELI LILLY AND COMPANY	-0.51%	-8.60%	+45.08%	+148.21%	995B
JOHNSON & JOHNSON	+0.20%	-4.42%	+49.05%	+50.81%	614B
ABBVIE INC.	-0.53%	-7.37%	+23.64%	+65.03%	431B
ROCHE HOLDING AG	+1.27%	-0.44%	+40.99%	+35.96%	353B
NOVARTIS AG	+0.66%	-3.88%	+30.62%	+38.79%	293B
ASTRAZENECA PLC	+3.76%	-11.54%	+3.55%	+6.72%	245B
NOVO NORDISK A/S	-5.42%	-13.27%	-4.15%	-46.27%	210B
AMGEN INC.	+2.94%	-0.78%	+29.17%	+60.32%	210B
GILEAD SCIENCES, INC.	+3.13%	+0.69%	+18.11%	+71.90%	168B
Average	+0.27%	-3.96%	+22.23%	+46.81%	351.84B
Weighted average by Cap.	+1.42%	-5.89%	+33.47%	+70.33%

	2024	2025
Net sales	2.09B 21.94M 19.05M 17.76M 16.32M 30.86M 31.2M 209M 81.86M 1.04B 82.39M 80.59M 3.46B	2.69B 28.25M 24.53M 22.87M 21.01M 39.73M 40.17M 270M 105M 1.34B 106M 104M 4.45B
Net income	225M 2.36M 2.05M 1.91M 1.76M 3.32M 3.36M 22.54M 8.81M 112M 8.87M 8.67M 372M	554M 5.82M 5.05M 4.71M 4.33M 8.19M 8.28M 55.55M 21.72M 277M 21.86M 21.38M 917M
Net Debt	-1.39B -14.61M -12.69M -11.83M -10.87M -20.55M -20.78M -139M -54.52M -695M -54.87M -53.67M -2.3B	-1.19B -12.56M -10.91M -10.17M -9.34M -17.67M -17.86M -120M -46.87M -597M -47.17M -46.14M -1.98B